Advertisement


Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Advertisement

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.



Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Cost of Care
Health-Care Policy

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement



Advertisement